Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kidswell Bio Corporation ( (JP:4584) ) has shared an announcement.
Kidswell Bio Corporation reported its financial results for the third quarter of fiscal 2025, outlining financial highlights alongside progress in its biosimilars and S-Quatre cell therapy businesses. The company also discussed its broader corporate strategy and investor relations activities, signaling continued efforts to strengthen its operational footprint and position in pediatric and family-focused healthcare solutions.
The most recent analyst rating on (JP:4584) stock is a Hold with a Yen256.00 price target. To see the full list of analyst forecasts on Kidswell Bio Corporation stock, see the JP:4584 Stock Forecast page.
More about Kidswell Bio Corporation
Kidswell Bio Corporation operates in the biotechnology sector, focusing on value creation within healthcare. The company is engaged in biosimilars and cell therapy businesses, aiming to support a comprehensive healthcare system for children, families, and society.
Average Trading Volume: 1,393,410
Technical Sentiment Signal: Buy
Current Market Cap: Yen12.15B
For detailed information about 4584 stock, go to TipRanks’ Stock Analysis page.